Compare KLA Corp. (KLAC) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KLA Corp. vs Vertex Pharmaceuticals Incorporated — how do they compare? KLA Corp. trades at $195.57 (market cap $256.72B), while Vertex Pharmaceuticals Incorporated trades at $510.08 (market cap $127.55B). The key difference: KLA Corp. is far larger — about 2× Vertex Pharmaceuticals Incorporated's market cap, and KLA Corp. pays a 0.47% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold KLA Corp. for 60 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| KLAC | VRTX | |
|---|---|---|
Market Cap | $256.72B | $127.55B |
Volume | 9,970,753 | 1,487,944 |
Sector | Technology | Health |
52-Week High | $301.71 | $557.96 |
52-Week Low | $98.28 | $407.37 |
Typical Hold Time | 60 Days | 120 Days |
Enterprise Value | $257.97B | $121.68B |
Dividend Yield | 0.47% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KLA Corporation (KLAC) trades at $196.72, showing minimal daily movement with strong fundamental performance. The stock maintains bullish technical signals with support at $193 and resistance at $201. Recent earnings consistently beat expectations, with Q2 2026 EPS of $1.05 exceeding the $1.00 forecast. The company demonstrates robust profitability with 35.57% net income margin and 87.5% ROE, supported by AI-driven semiconductor equipment demand and a $12.57 billion backlog.
Outlook remains positive with analyst consensus target of $223.88 offering 14% upside potential. Key opportunities include AI infrastructure growth and advanced packaging demand, while risks involve competitive pressure from Applied Materials and ASML, along with execution challenges in meeting ambitious $26 billion revenue target by 2030. Institutional ownership trends show continued confidence with recent acquisitions by Envestnet Portfolio Solutions.
Vertex Pharmaceuticals (VRTX) trades at $503.25, down 0.47% on the day, with a bearish technical signal despite strong fundamentals. The company maintains dominant cystic fibrosis market position with 86% gross margins and 35% net income margin. Recent positive Phase 2b data for inaxaplin in kidney disease shows pipeline expansion potential. Revenue grew to $12.0B in 2025 with $3.95B net income, recovering from 2024's loss.
Analyst consensus remains strongly bullish with 84% buy ratings and $573.50 price target, representing 14% upside. Key risks include pipeline execution and competitive pressures. The stock offers growth potential through gene therapy expansion but faces volatility from clinical trial outcomes and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About KLA Corp.
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
